| | Call Details | Amgen Earnings Conference Call (Q4 2012) Scheduled
to start Wed, Jan 23, 2013, 5:00 pm Eastern-- this event is ongoing now--
| | About Amgen Inc
(NasdaqGS:AMGN) | Other Calls | | Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and delivers human therapeutics based on advances in cellular and molecular biology primarily in the United States, Europe, and Canada. The company markets primarily recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN, which selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the bodys response to inflammatory diseases. The company also markets other products, including Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a human monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, its lead product in mid-to-late stage development include Denosumab, a human monoclonal antibody that targets a ligand, known as RANKL, an essential regulator of osteoclasts, which is under regulatory review. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. The company has various collaborative arrangements with Pfizer Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company, Limited; Array BioPharma Inc.; Kyowa Hakko Kirin Co. Ltd.; and Cytokinetics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. |
| More
Info:
Quote
|
Chart
|
News
|
Profile
|
Reports
|
Research
|
SEC
|
Msgs
|
Insider
|
Financials
|
Analyst Ratings |
|